Kite to License Cell Design Labs' Synthetic Biology Technology for
Applications in Acute Myeloid Leukemia with Exclusive Option for
Applications in B-cell Malignancies
Cell Design Labs' Reversible ‘On/Off Switch' Technology Provides
Dynamic Range of Control to Precisely Regulate Activity of Engineered
Collaboration Highlights Kite's Commitment to Access First-in-Class
Technologies for Next Generation Engineered CAR T-Cell Therapies
SANTA MONICA, Calif. & SAN FRANCISCO--(BUSINESS WIRE)--
Kite Pharma, Inc. (NASDAQ: KITE) ("Kite") and Cell Design Labs, Inc.
today announced a research collaboration and license agreement to
develop next generation, precision-controlled chimeric antigen receptor
(CAR) product candidates that incorporate Cell Design Labs' molecular
"on/off switch" technology.
The use of CARs to redirect T-cells against B-cell malignancies has
shown promise as a powerful tool to eradicate cancers. The switch
technology employs small molecule-mediated protein dimerization domains
to functionally activate the CAR and, similarly, to turn "off" the CAR
in the absence of the small molecule. By incorporating "on/off switches"
into next generation CAR products, physicians will have the potential to
rapidly control and reversibly titrate the activity of CAR T-cells.
Under the agreement, Cell Design Labs will develop "on/off switches" for
Kite's CAR T-cell pipeline. Kite will receive exclusive worldwide rights
to develop and commercialize CAR T-cell therapies containing Cell Design
Labs' "on/off switches" directed to certain targets for the treatment of
acute myeloid leukemia (AML). Kite also has the exclusive option to
develop and commercialize CAR T-cell products containing "on/off
switches" directed to certain targets for the treatment of B-cell
"Cell Design Labs was established to deploy exciting advances in
synthetic biology to build and control cell signaling networks through
our "on/off switch" technology," said Brian Atwood, Co-founder,
President, and Chief Executive Officer of Cell Design Labs. "Our
platform takes advantage of the modular design of CARs that we believe
will create a next generation of CARs whose activation can be titrated
or switched on and off by using small molecules that are clinically
available. We look forward to working with Kite, a company whose deep
understanding of CAR T-cell biology and manufacturing has already
generated advanced clinical programs for cancer patients."
"Kite remains highly focused on accessing important technologies that
could augment the activity and/or improve the safety of our engineered
T-cell therapy candidates," said Arie Belldegrun, M.D., FACS, Chairman,
President, and Chief Executive Officer of Kite. "Cell Design Labs has
developed an elegant approach to designing CARs. Our collaboration with
Cell Design Labs exemplifies Kite's commitment to bringing the next
generation CAR T-cell immunotherapies to patients."
Under the terms of the agreement, Kite will pay Cell Design Labs an
upfront payment and additional payments to support Cell Design Labs'
research. Cell Design Labs will be eligible to receive milestone
payments based upon the successful achievement of pre-specified
research, clinical, regulatory and commercial milestones, as well as
tiered royalties on product sales. Kite has increased its equity
investment in Cell Design Labs as part of Cell Design Labs' recent
private financings. Arie Belldegrun will join the Board of Directors of
Cell Design Labs and David Chang, M.D., Ph.D., Executive Vice President,
Research & Development, and Chief Medical Officer of Kite, will join as
a Board Observer.
About Kite Pharma, Inc.
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company engaged
in the development of novel cancer immunotherapy products, with a
primary focus on engineered autologous cell therapy (eACT™) designed to
restore the immune system's ability to recognize and eradicate tumors.
Kite is based in Santa Monica, CA. For more information on Kite Pharma,
please visit www.kitepharma.com.
Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
About Cell Design Labs, Inc.
Cell Design Labs is a biotherapeutics company pioneering breakthrough
science to develop disruptive cell-based therapies for cancer and other
devastating diseases. Based on innovative research from Dr. Wendell
Lim's lab at the University of California, San Francisco, Cell Design
Labs leverages the power of the body's immune system to develop smart,
living therapies with the capability to treat our most challenging
diseases with unprecedented power, precision, safety and durability.
Using its proprietary technology platform for custom cell engineering,
Cell Design Labs will develop its own portfolio of anti-cancer therapies
as well as create partnerships with leading oncology companies.
Initially focused on cancer, including both hematologic and solid
tumors, this broad technology may also have applications in other
complex diseases such as autoimmune and degenerative disorders. To learn
more about Cell Design Labs, please visit our website at: www.celldesignlabs.com.
Kite Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. The press release may, in some cases, use terms such as
"predicts," "believes," "potential," "proposed," "continue,"
"estimates," "anticipates," "expects," "plans," "intends," "may,"
"could," "might," "will," "should" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding intentions, beliefs, projections, outlook, analyses
or current expectations concerning, among other things: the ability to
research and develop CAR product candidates with Cell Design Labs'
"on/off switch" technology; the success of such product candidates and
the ability to control the activity of such product candidates; and the
ability to advance Kite's pipeline through new technologies. Various
factors may cause differences between Kite's expectations and actual
results as discussed in greater detail in Kite's filings with the
Securities and Exchange Commission, including without limitation in its
Form 10-Q filed with the SEC on May 9, 2016. Any forward-looking
statements that are made in this press release speak only as of the date
of this press release. Kite assumes no obligation to update the
forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160602005469/en/
Kite Pharma Contacts:
Design Labs Contact:
Source: Kite Pharma, Inc.
News Provided by Acquire Media